Terms: = Bone cancer AND EML4, ENSG00000143924, 27436
23 results:
1. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
2. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
3. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract] [Full Text] [Related]
4. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
Kemps PG; Picarsic J; Durham BH; Hélias-Rodzewicz Z; Hiemcke-Jiwa L; van den Bos C; van de Wetering MD; van Noesel CJM; van Laar JAM; Verdijk RM; Flucke UE; Hogendoorn PCW; Woei-A-Jin FJSH; Sciot R; Beilken A; Feuerhake F; Ebinger M; Möhle R; Fend F; Bornemann A; Wiegering V; Ernestus K; Méry T; Gryniewicz-Kwiatkowska O; Dembowska-Baginska B; Evseev DA; Potapenko V; Baykov VV; Gaspari S; Rossi S; Gessi M; Tamburrini G; Héritier S; Donadieu J; Bonneau-Lagacherie J; Lamaison C; Farnault L; Fraitag S; Jullié ML; Haroche J; Collin M; Allotey J; Madni M; Turner K; Picton S; Barbaro PM; Poulin A; Tam IS; El Demellawy D; Empringham B; Whitlock JA; Raghunathan A; Swanson AA; Suchi M; Brandt JM; Yaseen NR; Weinstein JL; Eldem I; Sisk BA; Sridhar V; Atkinson M; Massoth LR; Hornick JL; Alexandrescu S; Yeo KK; Petrova-Drus K; Peeke SZ; Muñoz-Arcos LS; Leino DG; Grier DD; Lorsbach R; Roy S; Kumar AR; Garg S; Tiwari N; Schafernak KT; Henry MM; van Halteren AGS; Abla O; Diamond EL; Emile JF
Blood; 2022 Jan; 139(2):256-280. PubMed ID: 34727172
[TBL] [Abstract] [Full Text] [Related]
5. Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis.
Takahara Y; Nakase K; Nojiri M; Kato R; Shinomiya S; Oikawa T; Mizuno S
Cancer Treat Res Commun; 2021; 28():100440. PubMed ID: 34325210
[TBL] [Abstract] [Full Text] [Related]
6. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.
Sui A; Song H; Li Y; Guo L; Wang K; Yuan M; Chen R
Medicine (Baltimore); 2021 Feb; 100(8):e24917. PubMed ID: 33663128
[TBL] [Abstract] [Full Text] [Related]
7. The Prevalence of the eml4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma.
Heriyanto DS; Trisnawati I; Kumara EG; Laiman V; Yuliani FS; Sumpono ASB; Cempaka R; Marcellus ; Budiono E
Pulm Med; 2020; 2020():3578748. PubMed ID: 33425389
[TBL] [Abstract] [Full Text] [Related]
8. Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.
Quelen C; Grand D; Sarot E; Brugières L; Sibon D; Pradines A; Laurent C; Brousset P; Lamant L
J Mol Diagn; 2021 Feb; 23(2):131-139. PubMed ID: 33246076
[TBL] [Abstract] [Full Text] [Related]
9. Spindle cell neoplasm with eml4-ALK gene fusion presenting as an intraosseous vertebral mass.
Mantilla JG; Cheung H; Ha AS; Hoch BL; Liu YJ; Ricciotti RW
Genes Chromosomes Cancer; 2021 Apr; 60(4):282-286. PubMed ID: 33170538
[TBL] [Abstract] [Full Text] [Related]
10. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and eml4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract] [Full Text] [Related]
11. ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.
Qiu Y; Li B; Zhang Y; Guo X; Xiang C; Wang C; Lu Y; Ren S; Zhao J
Medicine (Baltimore); 2019 Mar; 98(11):e14826. PubMed ID: 30882666
[TBL] [Abstract] [Full Text] [Related]
12. An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
Corrales-Rodríguez L; Arrieta O; Mas L; Báez-Saldaña R; Castillo-Fernández O; Blais N; Martín C; Juárez M; Khanna P; Ramos-Esquivel A; Bacon L; Rojas L; Wills B; Oblitas G; Pérez MA; Cuello M; Cardona AF;
Lung Cancer; 2017 Nov; 113():30-36. PubMed ID: 29110845
[TBL] [Abstract] [Full Text] [Related]
13. Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies.
Cipriani NA; Agarwal S; Dias-Santagata D; Faquin WC; Sadow PM
Thyroid; 2017 Jun; 27(6):819-824. PubMed ID: 28293986
[TBL] [Abstract] [Full Text] [Related]
14. Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.
Gasparini P; Casanova M; Villa R; Collini P; Alaggio R; Zin A; Bonvini P; Antonescu CR; Boldrini R; Caserini R; Moro M; Centonze G; Meazza C; Massimino M; Bergamaschi L; Luksch R; Chiaravalli S; Bisogno G; Zaffaroni N; Daidone MG; Sozzi G; Ferrari A
Oncotarget; 2016 Sep; 7(37):58903-58914. PubMed ID: 27385213
[TBL] [Abstract] [Full Text] [Related]
15. A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.
Xu CW; Cai XY; Shao Y; Li Y; Shi MW; Zhang LY; Wang L; Zhang YP; Wang LP; Tian YW
Mol Med Rep; 2015 Sep; 12(3):4370-4375. PubMed ID: 26130140
[TBL] [Abstract] [Full Text] [Related]
16. [Atypical metastatic breast localization in lung cancer].
Serraille A; Barazzutti H; Greillier L; Barlesi F
Rev Mal Respir; 2015 Nov; 32(9):953-5. PubMed ID: 26037683
[TBL] [Abstract] [Full Text] [Related]
17. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human eml4-ALK lung cancer cell line.
Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
[TBL] [Abstract] [Full Text] [Related]
18. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.
Bosc C; Ferretti GR; Cadranel J; Audigier-Valette C; Besse B; Barlesi F; Decroisette C; Lantuejoul S; Arbib F; Moro-Sibilot D
Target Oncol; 2015 Jun; 10(2):247-53. PubMed ID: 25119973
[TBL] [Abstract] [Full Text] [Related]
19. Combined point mutation in KRAS or EGFR genes and eml4-ALK translocation in lung cancer patients.
Jürgens J; Engel-Riedel W; Prickartz A; Ludwig C; Schildgen O; Tillmann RL; Stoelben E; Brockmann M; Schildgen V
Future Oncol; 2014 Mar; 10(4):529-32. PubMed ID: 24754584
[TBL] [Abstract] [Full Text] [Related]
20. Lung cancer during pregnancy: an unusual case.
Neves I; Mota PC; Hespanhol VP
Rev Port Pneumol; 2014; 20(1):46-9. PubMed ID: 23910397
[TBL] [Abstract] [Full Text] [Related]
[Next]
